As of today (2024-04-19), Revance Therapeutics's share price is $3.82. Revance Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-1.84. Hence, Revance Therapeutics's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for Revance Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Revance Therapeutics's highest Price to Tangible Book Ratio was 12.57. The lowest was 2.28. And the median was 3.82.
RVNC's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.7 * Ranked among companies with meaningful Price-to-Tangible-Book only.
A closely related ratio is called PB Ratio. As of today, Revance Therapeutics's share price is $3.82. Revance Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $-1.72. Hence, Revance Therapeutics's P/B Ratio of today is .
Revance Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Revance Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Revance Therapeutics Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
3.77
12.57
-
-
-
Revance Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
-
-
-
-
-
Competitive Comparison
For the Biotechnology subindustry, Revance Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revance Therapeutics Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Revance Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Revance Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Revance Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Revance Therapeutics (Revance Therapeutics) Business Description
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVNC has been successfully added to your 